XBRANE — Xbrane Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK235.93m
- SEK262.45m
- SEK152.35m
Brief: Xbrane To Sell Xb003, Parts Of Its Organization To Alvotech
Brief: Xbrane Biopharma Proposes No Dividend For 2024
Brief: Xbrane Biopharma Q4 EBITDA SEK -23.2 Million
Brief: Xbrane Biopharma Appoints Jane Benyamin Acting CFO
Brief: Xbrane Biopharma AB - Re-Submits BLA For Ranibizumab Biosimilar To FDA
Brief: Systematic Group Provides Short-Term Loan Of SEK 20 Mln To Xbrane Biopharma
Brief: Xbrane, Intas To Develop Nivolumab Biosimilar
Brief: Xbrane Biopharma Q3 EBITDA SEK -28.9 Million
Brief: Xbrane Biopharma: Update On Out-Licensing Of Xdivane, Xb003
Brief: Xbrane Biopharma Gets Scientific Advice From FDA On Development Of Xdivane
Brief: Xbrane Biopharma Positive Operating Cash Flow Is Expected To Be Achieved In Q2 2025
Brief: Xbrane Biopharma Q2 EBITDA SEK -54.7 Million
Brief: Xbrane Biopharma - Update On Out-Licensing, Financial Position
Brief: Xbrane Biopharma Q1 EBITDA SEK -76 Million
Brief: Xbrane, STADA Partner With Valorum To Commercialize Ranibizumab Biosimilar Candidate In US
Brief: Avanza Pension Cuts Stake In Xbrane Biopharma From Above 5% To 4.4%
Brief: Xbrane Biopharma Received Complete Response Letter From FDA
Brief: Xbrane Biopharma To Raise SEK 337.2 Million Through Rights Issue
Brief: Xbrane Gets Additional Subscription Undertakings Of About SEK 18.1 Mln